Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study. IMproveMF update: Phase 1/1B trial of ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...

Emergency hemopoiesis may maintain blood counts and a proinflammatory environment in MDS, AML, and ICUS. Altered neutrophil subset distributions in MDS and AML show diagnostic sensitivity, with ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...

AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...